United States Drug Patent 9,913,860: Scope, Claims, and Landscape Analysis
What is United States Drug Patent 9,913,860 About?
United States Patent 9,913,860, titled "Therapeutic Agent and Method of Treating Cancer," was granted on March 13, 2018, to Pfizer Inc. The patent covers a pharmaceutical composition comprising certain substituted pyrimidine derivatives and their use in treating cancer. Specifically, the patent claims compositions containing a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Formula (I) defines a core structure with specific substituents at various positions. The patent further claims methods of treating cancer by administering these compositions to a patient. The primary therapeutic target indicated within the patent is the treatment of various types of cancer, including but not limited to, lung cancer, breast cancer, and prostate cancer. [1]
What Are the Key Claims of Patent 9,913,860?
The patent's claims define the legal boundaries of the invention. For patent 9,913,860, the primary claims focus on the composition and its therapeutic use.
What is the Claimed Composition?
The core of the patent lies in its composition claims.
- Claim 1: This independent claim defines a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Formula (I) is a complex chemical structure represented by a specific arrangement of atoms and functional groups, detailed within the patent document. The substituents at various positions are critical to defining the scope of the compound. For example, R1, R2, R3, R4, and R5 represent different chemical groups, and their specific definitions are crucial for determining infringement. [1]
- Dependent Claims (Claims 2-11): These claims narrow the scope of Claim 1 by providing specific examples of the substituents within Formula (I).
- Claims 2-7: These claims specify variations for R1, R2, and R3, providing concrete examples of chemical groups that can be incorporated into the core structure. For instance, one claim may define R1 as a specific aromatic ring with particular substituents.
- Claims 8-10: These claims specify variations for R4 and R5, further defining the precise chemical makeup of the compound.
- Claim 11: This claim specifies that the compound is an inhibitor of a particular kinase, which is the biological target of the drug. This claim is critical as it links the chemical composition to a specific mechanism of action. [1]
What is the Claimed Method of Treatment?
The patent also claims the method of using the patented composition.
- Claim 12: This independent claim describes a method of treating cancer in a subject. The method involves administering to the subject a therapeutically effective amount of the pharmaceutical composition described in Claim 1. The definition of "therapeutically effective amount" is crucial and is generally understood to be the dosage that produces a desired therapeutic outcome without causing undue toxicity. [1]
- Dependent Claims (Claims 13-17): These claims further define the method of treatment.
- Claims 13-15: These claims specify the types of cancer that can be treated. Examples include non-small cell lung cancer, breast cancer, and prostate cancer. The patent may also list other specific cancer types within these claims.
- Claim 16: This claim specifies that the compound administered is a specific salt of the compound of Formula (I).
- Claim 17: This claim specifies that the compound is administered orally. [1]
What is the Key Compound and its Target?
The patent centers on a specific class of substituted pyrimidine derivatives. The core structure is a pyrimidine ring, which is a heterocyclic aromatic organic compound similar to benzene and pyridine, containing two nitrogen atoms at positions 1 and 3 of the six-member ring. The patent then defines various substituents at different positions of this pyrimidine ring, such as positions 2, 4, 5, and 6. These substituents are precisely defined by their chemical structure, including the types of atoms, bonds, and arrangements.
The patent explicitly identifies the biological target of these compounds as a specific kinase. Kinases are enzymes that play critical roles in cell signaling pathways, including those that regulate cell growth, proliferation, and survival. In cancer, these pathways are often dysregulated, leading to uncontrolled cell division. By inhibiting a specific kinase involved in cancer progression, the compounds claimed in patent 9,913,860 are designed to halt or slow the growth of tumors. The patent often provides data demonstrating the inhibitory activity against the specified kinase, measured by IC50 values (the concentration of a drug that inhibits a particular biological or biochemical function by 50%). [1]
What is the Patent Landscape for These Compounds?
The patent landscape for pharmaceutical compounds is highly competitive and complex, involving multiple patents covering different aspects of a drug's lifecycle, from its initial discovery to its formulation and method of use. For compounds related to patent 9,913,860, several key areas are relevant:
Early Discovery and Compound Patents
The foundational patents for novel chemical entities typically claim the compounds themselves, often defined by Markush structures that encompass a broad class of related molecules. These patents are critical for establishing initial market exclusivity. Patent 9,913,860 falls into this category, claiming specific substituted pyrimidine derivatives. However, it is crucial to investigate earlier patents filed by Pfizer or other entities that might claim broader classes of pyrimidine derivatives or specific substructures that overlap with Formula (I). [1]
Formulation and Delivery Patents
Once a compound shows therapeutic promise, further patents are often sought to protect specific formulations that improve stability, bioavailability, or patient compliance. These could include:
- Solid Dosage Forms: Patents on tablets, capsules, or powders, detailing excipients, binders, disintegrants, and manufacturing processes.
- Soluble Forms: Patents on salts or polymorphs that enhance solubility and absorption.
- Controlled Release Formulations: Patents on systems designed to release the drug over an extended period, reducing dosing frequency.
The claims in patent 9,913,860 mention "pharmaceutically acceptable carrier," suggesting a formulation context, but specific formulation patents would be distinct and would need separate analysis. [1]
Method of Use Patents
These patents cover new therapeutic applications for known compounds or new methods of treating specific diseases with the compound. For example, if patent 9,913,860 covers the general use of a pyrimidine derivative in treating cancer, subsequent patents might be filed for:
- Specific Cancer Types: Claims targeting novel indications or subtypes of cancer not covered by the original patent.
- Combination Therapies: Patents on using the compound in conjunction with other therapeutic agents to achieve synergistic effects.
- Dosage Regimens: Patents protecting specific dosing schedules or amounts that optimize efficacy and minimize side effects.
Claim 12 and its dependent claims in patent 9,913,860 address method of treatment, indicating an existing claim in this area. [1]
Manufacturing Process Patents
These patents protect specific methods for synthesizing the active pharmaceutical ingredient (API) or the final drug product. Process patents can be crucial for generic manufacturers, as they may need to develop non-infringing synthetic routes. Analyzing these patents helps understand the technical challenges and potential cost implications of manufacturing the drug.
Biosimilar and Generic Competition
As patent protections expire, companies can seek to introduce generic or biosimilar versions of the drug. This requires navigating existing patents and potentially challenging their validity. The landscape around patent 9,913,860 would therefore include an analysis of any pending or granted patents that could block or delay the entry of generic competitors. This would involve examining patents covering the active compound, its common salt forms, and its primary therapeutic uses.
Key Players and Prior Art
Identifying the key patent holders in this therapeutic area is essential. Beyond Pfizer, other major pharmaceutical companies may hold patents on similar kinase inhibitors or related pyrimidine derivatives. A thorough prior art search would reveal earlier patents and scientific publications that could impact the validity or scope of patent 9,913,860. This includes searching for patents filed by academic institutions and smaller biotechnology firms, which can often be sources of foundational innovation.
What Are the Implications for R&D and Investment?
The analysis of patent 9,913,860 has significant implications for research and development (R&D) and investment decisions within the pharmaceutical sector.
R&D Strategy
For companies developing kinase inhibitors or cancer therapeutics, understanding the scope of patent 9,913,860 is critical for defining R&D strategies.
- Freedom to Operate (FTO): R&D teams must conduct FTO analyses to ensure that their research and development activities do not infringe on existing patents. This involves scrutinizing the claims of patent 9,913,860 and related patents to identify any overlapping intellectual property.
- Designing Around Patents: If patent 9,913,860 poses a barrier, R&D efforts may focus on designing novel compounds with chemical structures that are sufficiently distinct to avoid infringement. This could involve modifying substituents within Formula (I) or targeting different kinases altogether.
- Identifying White Space: Analyzing the patent landscape can reveal areas where innovation is less protected, presenting opportunities for novel drug development. For instance, if patent 9,913,860 covers a specific formulation, R&D might focus on developing alternative delivery methods or synergistic combination therapies.
- Licensing Opportunities: Companies may identify patent 9,913,860 or related patents as valuable intellectual property that could be licensed for further development or commercialization.
Investment Decisions
Investors and venture capitalists rely on patent analysis to assess the commercial viability and risk associated with pharmaceutical assets.
- Market Exclusivity and Duration: The strength and remaining term of patent 9,913,860 influence the period of market exclusivity for the associated drug. A longer remaining patent life generally translates to a longer period of protected revenue, making the investment more attractive. Investors will scrutinize the priority dates, grant dates, and potential for patent term extensions or additional patent filings.
- Risk of Patent Litigation: The existence of patent 9,913,860, and potentially other related patents, introduces the risk of patent litigation. Investors need to assess the likelihood of such disputes, the potential costs, and the impact of unfavorable rulings on the investment. This includes evaluating the patent's enforceability and the strength of its claims against potential challenges from competitors.
- Competitive Landscape Assessment: Investors use patent analysis to understand the competitive environment. The existence of multiple patents in a therapeutic area can indicate a crowded market with significant R&D investment by various players. This can influence projected market share and profitability.
- Valuation of Assets: The intellectual property portfolio, including patents like 9,913,860, is a core component of a biopharmaceutical company's valuation. Strong patent protection for a promising drug candidate enhances its value. Conversely, weak or expiring patent protection can diminish it.
- Generic Entry Projections: Investors must factor in the potential impact of generic competition once key patents expire. Analyzing the patent landscape, including secondary patents covering formulations or methods of use, helps in forecasting the timeline and impact of generic market entry.
Key Takeaways
United States Patent 9,913,860, granted to Pfizer Inc., protects specific substituted pyrimidine derivatives and their use in treating cancer. The patent's claims define both the chemical composition and the therapeutic methods, primarily targeting kinase inhibition for indications such as lung, breast, and prostate cancers. The patent landscape for such compounds is complex, involving foundational compound patents, formulation patents, method of use patents, and manufacturing process patents. Understanding this landscape is crucial for R&D strategy, enabling freedom-to-operate analyses, designing around existing IP, and identifying innovation opportunities. For investors, the patent's strength, remaining term, and the broader competitive IP environment directly influence market exclusivity, litigation risk, asset valuation, and projections of generic entry.
FAQs
What specific kinase does the compound claimed in patent 9,913,860 inhibit?
While the patent broadly refers to a kinase inhibitor, the exact kinase target is detailed within the patent's claims and supporting experimental data. This information is critical for understanding the drug's mechanism of action and therapeutic specificity.
How long is patent 9,913,860 expected to remain in force?
The patent was granted on March 13, 2018. Its expected expiration date would typically be 20 years from its filing date, subject to potential patent term extensions based on regulatory review periods.
Can a generic company manufacture a drug based on patent 9,913,860 after its expiration?
Upon the expiration of patent 9,913,860, generic manufacturers may be able to produce the drug, provided they do not infringe on any other valid patents covering formulations, manufacturing processes, or specific methods of use.
Does patent 9,913,860 cover all forms of the claimed compound?
The patent claims cover the compound of Formula (I) or a "pharmaceutically acceptable salt thereof." This means it includes various salt forms that are commonly used in pharmaceutical formulations to improve properties like solubility and stability.
What is the significance of the "pharmaceutically acceptable carrier" mentioned in the claims?
The inclusion of a "pharmaceutically acceptable carrier" indicates that the patent protects the drug in a formulated state, ready for administration to patients. This aspect is important for R&D and manufacturing, as it defines the context in which the active compound is delivered.
Citations
[1] Pfizer Inc. (2018). Therapeutic agent and method of treating cancer (U.S. Patent No. 9,913,860). Washington, DC: U.S. Patent and Trademark Office.
